



FOR IMMEDIATE RELEASE:

Bioniche Life Sciences Inc. Announces its Intention to Delist from the ASX

BELLEVILLE, ON, December 1, 2013 – Bioniche Life Sciences Inc. (TSX: BNC, ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that, given the very low level of trading on the Australian Securities Exchange (ASX), the small number of CDIs remaining, and the significant liquidity for Bioniche shares on the Toronto Stock Exchange (TSX), it intends to delist from the official list of the ASX, in the first half of 2014, subject to ASX approval. As a result of the delisting, the Company expects to realize a savings in administrative and compliance obligations.

All holders of CDIs will be offered several alternatives, including selling or transferring their holdings to the TSX where there is a more liquid market. CDI holders will be sent an information package in due course which explains in detail the options available to them. It is important that CDI holders take time to consider this information package carefully.

Assuming that ASX approval is granted, the delisting of Bioniche from the ASX is expected to result in some cost savings for the Company. Following the delisting, Bioniche Common Shares will continue to trade on the TSX.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and One Health. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For further information, please contact:

Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.

Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058

Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097

Jennifer.Shea@Bioniche.com